We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

You are here

Magazine

7

New scientific publication on RHINOSECTAN®

A new publication carried out in a nasal mucosa model demonstrates the barrier effect of Rhinosectan®, which confirms its utility in nasal respiratory diseases such as allergic rhinitis. Rhinosectan® is a Class I medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE, Noventure SL) De Servi B et al. Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study. Allergy Asthma Clin Immunol. 2017 Aug 10;13:37

Read more

Congresses: Noventure participates at NeuroGASTRO 2017, Cork, Ireland, with an innovative approach to IBS

Noventure, as part of its continued commitment to Gastroenterology, participated at the recent NeuroGASTRO 2017 meeting, which brought together leading experts and young investigators in neurogastroenterology, digestive motility and functional gastrointestinal diseases from Europe and from all around the world. The new product Gelsectan® was depicted at the Noventure´s stand as a teaser campaign, under the motto “Mucoprotection”.

Read more

Let's meet in..

2018, Aug 29

FNM 2018

FNM-2018-Amsterdam
Read more

2018, Oct 09

CPHI

Read more

2018, Oct 24

UEG Week 2018

Read more

2018, Nov 26

EuroPLX 68

Read more

2018, Nov 29

PharmaVenue November 2018

Read more